Analysts Set Karyopharm Therapeutics Inc. (NASDAQ:KPTI) PT at $45.60

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have earned a consensus recommendation of “Buy” from the five research firms that are covering the stock, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $43.20.

Several equities research analysts have commented on the company. HC Wainwright boosted their target price on Karyopharm Therapeutics from $7.00 to $56.00 and gave the company a “buy” rating in a research note on Wednesday, February 26th. Royal Bank of Canada dropped their price target on Karyopharm Therapeutics from $34.00 to $33.00 and set an “outperform” rating on the stock in a research note on Tuesday. StockNews.com cut Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday. Robert W. Baird lowered their price objective on Karyopharm Therapeutics from $54.00 to $42.00 and set an “outperform” rating on the stock in a research report on Tuesday. Finally, Barclays increased their target price on Karyopharm Therapeutics from $5.00 to $10.00 and gave the stock an “overweight” rating in a report on Tuesday.

Karyopharm Therapeutics Trading Up 12.2%

NASDAQ:KPTI opened at $5.44 on Tuesday. The stock has a market cap of $46.62 million, a price-to-earnings ratio of -5.33 and a beta of 0.33. The stock has a 50-day moving average price of $5.41 and a two-hundred day moving average price of $8.79. Karyopharm Therapeutics has a 1 year low of $3.51 and a 1 year high of $17.85.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Monday, May 12th. The company reported ($2.77) earnings per share for the quarter, beating the consensus estimate of ($4.21) by $1.44. The business had revenue of $30.02 million for the quarter, compared to the consensus estimate of $35.12 million. Sell-side analysts forecast that Karyopharm Therapeutics will post -0.71 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Two Sigma Investments LP boosted its holdings in Karyopharm Therapeutics by 60.3% in the fourth quarter. Two Sigma Investments LP now owns 137,786 shares of the company’s stock valued at $93,000 after acquiring an additional 51,856 shares during the last quarter. Two Sigma Advisers LP boosted its holdings in shares of Karyopharm Therapeutics by 145.5% during the 4th quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock worth $52,000 after buying an additional 45,400 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Karyopharm Therapeutics by 23.5% in the 4th quarter. Northern Trust Corp now owns 283,729 shares of the company’s stock worth $192,000 after purchasing an additional 54,061 shares in the last quarter. Jane Street Group LLC lifted its holdings in shares of Karyopharm Therapeutics by 265.5% in the 4th quarter. Jane Street Group LLC now owns 748,306 shares of the company’s stock worth $506,000 after purchasing an additional 543,556 shares in the last quarter. Finally, Focus Partners Wealth purchased a new stake in Karyopharm Therapeutics in the 4th quarter valued at $31,000. Institutional investors and hedge funds own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).